View in EDS

Discovery and systematic characterization of risk variants and genes for coronary artery disease in over a million participants

Saved in:
Bibliographic Details
Title: Discovery and systematic characterization of risk variants and genes for coronary artery disease in over a million participants
Authors: Aragam, K.G., Jiang, T., Goel, A., Kanoni, S., Wolford, B.N., Atri, D.S., Weeks, E.M., Wang, M., Hindy, G., Zhou, W., Grace, C., Roselli, C., Marston, N.A., Kamanu, F.K., Surakka, I., Venegas, L.M., Sherliker, P., Koyama, S., Ishigaki, K., Åsvold, B.O., Brown, M.R., Brumpton, B., de Vries, P.S., Giannakopoulou, O., Giardoglou, P., Gudbjartsson, D.F., Güldener, U., Haider, S.M.I., Helgadottir, A., Ibrahim, M., Kastrati, A., Kessler, T., Kyriakou, T., Konopka, T., Li, L., Ma, L., Meitinger, T., Mucha, S., Munz, M., Murgia, F., Nielsen, J.B., Nöthen, M.M., Pang, S., Reinberger, T., Schnitzler, G., Smedley, D., Thorleifsson, G., von Scheidt, M., Ulirsch, J.C., Danesh, J., Arnar, D.O., Burtt, N.P., Costanzo, M.C., Flannick, J., Ito, K., Jang, D.-K., Kamatani, Y., Khera, A.V., Komuro, I., Kullo, I.J., Lotta, L.A., Nelson, C.P., Roberts, R., Thorgeirsson, G., Thorsteinsdottir, U., Webb, T.R., Baras, A., Björkegren, J.L.M., Boerwinkle, E., Dedoussis, G., Holm, H., Hveem, K., Melander, O., Morrison, A.C., Orho-Melander, M., Rallidis, L.S., Ruusalepp, A., Sabatine, M.S., Stefansson, K., Zalloua, P., Ellinor, P.T., Farrall, M., Ruff, C.T., Finucane, H.K., Hopewell, J.C., Clarke, R., Gupta, R.M., Erdmann, J., Samani, N.J., Schunkert, H., Watkins, H., Willer, C.J., Deloukas, P., Kathiresan, S., Butterworth, A.S., Biobank Japan, EPIC-CVD, The CARDIoGRAMplusC4D Consortium
Publisher Information: 2022.
Publication Year: 2022
Subject Terms: 16. Peace & justice, 3. Good health
Description: The discovery of genetic loci associated with complex diseases has outpaced the elucidation of mechanisms of disease pathogenesis. Here we conducted a genome-wide association study (GWAS) for coronary artery disease (CAD) comprising 181,522 cases among 1,165,690 participants of predominantly European ancestry. We detected 241 associations, including 30 new loci. Cross-ancestry meta-analysis with a Japanese GWAS yielded 38 additional new loci. We prioritized likely causal variants using functionally informed fine-mapping, yielding 42 associations with less than five variants in the 95% credible set. Similarity-based clustering suggested roles for early developmental processes, cell cycle signaling and vascular cell migration and proliferation in the pathogenesis of CAD. We prioritized 220 candidate causal genes, combining eight complementary approaches, including 123 supported by three or more approaches. Using CRISPR–Cas9, we experimentally validated the effect of an enhancer in MYO9B, which appears to mediate CAD risk by regulating vascular cell motility. Our analysis identifies and systematically characterizes >250 risk loci for CAD to inform experimental interrogation of putative causal mechanisms for CAD. © 2022, The Author(s).
Document Type: Article
Language: Greek
Access URL: https://pergamos.lib.uoa.gr/uoa/dl/object/3345712
Accession Number: edsair.od......2127..8e02d934aebbe19c1eb9b059c20addb8
Database: OpenAIRE
Description
Abstract:The discovery of genetic loci associated with complex diseases has outpaced the elucidation of mechanisms of disease pathogenesis. Here we conducted a genome-wide association study (GWAS) for coronary artery disease (CAD) comprising 181,522 cases among 1,165,690 participants of predominantly European ancestry. We detected 241 associations, including 30 new loci. Cross-ancestry meta-analysis with a Japanese GWAS yielded 38 additional new loci. We prioritized likely causal variants using functionally informed fine-mapping, yielding 42 associations with less than five variants in the 95% credible set. Similarity-based clustering suggested roles for early developmental processes, cell cycle signaling and vascular cell migration and proliferation in the pathogenesis of CAD. We prioritized 220 candidate causal genes, combining eight complementary approaches, including 123 supported by three or more approaches. Using CRISPR–Cas9, we experimentally validated the effect of an enhancer in MYO9B, which appears to mediate CAD risk by regulating vascular cell motility. Our analysis identifies and systematically characterizes >250 risk loci for CAD to inform experimental interrogation of putative causal mechanisms for CAD. © 2022, The Author(s).